US drug developers question benefit of REMS initiative
This article was originally published in SRA
Executive Summary
Key US healthcare stakeholders including drug developers, healthcare providers and insurance companies are uncertain about the benefits of a risk evaluation programme introduced three years ago by the Food and Drug Administration, according to a survey by the Tufts Center for the Study of Drug Development1.
You may also be interested in...
Hoops, hoopla, big ideas and diabetes
Perhaps only a man who inherited an enthusiasm for peptides could, without a trace of irony, cast diabetes drug development as the work of a pastry chef. But for David Solomon, the son of a peptide devotee, mixed metaphors and stretched comparisons are simply the spray thrown up by his unbridled enthusiasm for his chosen trade, that of basketball coach to GLP-1 receptor agonist developer Zealand Pharma.
How Dennis Gillings took a gamble and built a $3.7bn business
"How the hell will Glaxo need you? You've only got a few people, they've got about 50,000!"